Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1978 May;32(2):193-8.

Circulating soluble immume complexes in recurrent oral ulceration and Behçet's syndrome

Circulating soluble immume complexes in recurrent oral ulceration and Behçet's syndrome

R J Levinsky et al. Clin Exp Immunol. 1978 May.

Abstract

Circulating IgG immune complexes were assayed by means of agglutination inhibition of IgG-coated latex particles to human IgG by rabbit IgM antibodies. Sera from thirty patients with Behçet's syndrome, thirty patients with recurrent oral ulcers and thirty healthy control subjects were analysed. The results showed raised levels of immune complexes in 60% of patients with Behçet's syndrome and 40% of patients with recurrent oral ulcers. There were significant differences in the levels of immune complexes between the neuro-ocular and arthritic types of Behçet's syndrome as compared with the muco-cutaneous type of Behçet's syndrome or recurrent oral ulceration. A close association was found between the disease activity and the amount of immune complexes. These results suggest that immune complexes may play a part in the transition from the epithelial involvement of mucosa or cutaneous tissues to the neuro-ocular and arthritic types of Behçet's syndrome. Another factor in tissue distribution might be the size of immune complexes, as multi-focal involvement of tissues in the neuro-ocular type of Behçet's syndrome is associated with a broad range of immune complexes from 3 X 10(5) to 3 X 10(6) daltons.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Lancet. 1964 Nov 28;2(7370):1154-5 - PubMed
    1. Br Med J. 1967 Feb 25;1(5538):465-7 - PubMed
    1. Lancet. 1977 Mar 12;1(8011):564-7 - PubMed
    1. Br Med J. 1977 May 28;1(6073):1387-9 - PubMed
    1. Clin Exp Immunol. 1977 Sep;29(3):428-35 - PubMed

LinkOut - more resources